当前位置:首页 - 行情中心 - 天坛生物(600161) - 财务分析 - 现金流量表

天坛生物

(600161)

  

流通市值:294.23亿  总市值:294.23亿
流通股本:19.77亿   总股本:19.77亿

现金流量表

报告期2025-12-312025-09-302025-06-302025-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金4,734,373,938.473,075,023,127.551,736,558,359.18681,035,737.88
  收到的税费返还---7,800
  收到其他与经营活动有关的现金81,028,757.383,623,172.2149,939,140.2821,960,381.56
  经营活动现金流入小计4,815,402,695.773,158,646,299.761,786,497,499.46703,003,919.44
  购买商品、接受劳务支付的现金2,267,585,618.381,611,489,389.791,039,889,364.45503,200,062.74
  支付给职工以及为职工支付的现金1,212,164,096.4669,693,580.99445,464,366.1238,229,201.95
  支付的各项税费767,125,365.15586,001,241.1399,920,918.5218,444,163.72
  支付其他与经营活动有关的现金229,780,957.21174,567,059.81103,127,400.5344,770,204.23
  经营活动现金流出小计4,476,656,037.143,041,751,271.691,988,402,049.581,004,643,632.64
  经营活动产生的现金流量净额338,746,658.63116,895,028.07-201,904,550.12-301,639,713.2
二、投资活动产生的现金流量:
  取得投资收益收到的现金37,196,956.9637,100,956.9637,100,956.96-
  处置固定资产、无形资产和其他长期资产收回的现金净额339,337.03138,228.379,930.752,446.7
  收到的其他与投资活动有关的现金709,000,000700,000,000700,000,000-
  投资活动现金流入小计746,536,293.99737,239,185.26737,180,887.6652,446.7
  购建固定资产、无形资产和其他长期资产支付的现金605,531,434.31450,530,338.98325,460,519.56144,405,613.98
  支付其他与投资活动有关的现金16,650,000---
  投资活动现金流出小计622,181,434.31450,530,338.98325,460,519.56144,405,613.98
  投资活动产生的现金流量净额124,354,859.68286,708,846.28411,720,368.1-144,353,167.28
三、筹资活动产生的现金流量:
  取得借款收到的现金286,925,081.38252,966,301.4242,137,862.6334,737,094.71
  筹资活动现金流入小计286,925,081.38252,966,301.4242,137,862.6334,737,094.71
  分配股利、利润或偿付利息支付的现金706,612,364.61706,402,398.36304,247,963.18-
  其中:子公司支付给少数股东的股利、利润212,269,503.11212,269,503.11107,143,523.23-
  支付其他与筹资活动有关的现金22,708,405.5718,726,597.110,930,606.632,068,648.47
  筹资活动现金流出小计729,320,770.18725,128,995.46315,178,569.812,068,648.47
  筹资活动产生的现金流量净额-442,395,688.8-472,162,694.04-273,040,707.1832,668,446.24
四、汇率变动对现金及现金等价物的影响-28,934.14-9,499.67-2,279.48370.01
五、现金及现金等价物净增加额20,676,895.37-68,568,319.36-63,227,168.68-413,324,064.23
  加:期初现金及现金等价物余额1,422,920,905.041,422,920,905.041,422,920,905.041,422,920,905.04
  期末现金及现金等价物余额1,443,597,800.411,354,352,585.681,359,693,736.361,009,596,840.81
补充资料:
  净利润1,489,882,179.7-865,800,086.14-
  资产减值准备19,110,612.28-33,550,584.65-
  固定资产和投资性房地产折旧348,834,129.26-163,520,008.34-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧348,834,129.26-163,520,008.34-
  无形资产摊销76,618,593.93-37,830,420.75-
  长期待摊费用摊销32,280,975.62-16,831,522.75-
  处置固定资产、无形资产和其他长期资产的损失-104,452.59--204,679.09-
  固定资产报废损失2,875,975.18-54,096.04-
  财务费用7,364,956.02-4,340,269.9-
  投资损失-29,398,010.78--22,432,891.35-
  递延所得税-12,871,040.86--10,792,107.38-
  其中:递延所得税资产减少-14,651,807.57--4,514,683.67-
    递延所得税负债增加1,780,766.71--6,277,423.71-
  存货的减少-172,036,268.91--40,628,592.84-
  经营性应收项目的减少-1,375,668,968.71--1,340,914,398.19-
  经营性应付项目的增加-113,339,500.64-78,271,390.42-
  现金的期末余额1,443,597,800.41-1,359,693,736.36-
  减:现金的期初余额1,422,920,905.04-1,422,920,905.04-
  现金及现金等价物的净增加额20,676,895.37--63,227,168.68-
公告日期2026-03-282025-10-252025-08-222025-04-26
审计意见(境内)标准无保留意见
TOP↑